Annual report pursuant to Section 13 and 15(d)

Equity (Details Textual)

v3.20.1
Equity (Details Textual) - USD ($)
1 Months Ended 12 Months Ended
Dec. 13, 2019
Jan. 09, 2019
Aug. 08, 2018
Apr. 25, 2019
Feb. 27, 2019
Apr. 23, 2018
Mar. 27, 2018
Dec. 31, 2019
Dec. 31, 2018
Mar. 03, 2017
Common shares sold for cash               $ 1,673,088    
Common shares issued for services                 $ 1,371,450  
Stock-based compensation expense               9,209,147 3,092,981  
Common stock issued, Shares         158,932          
Warrants to purchase common stock         200,000          
Stock-based compensation expense stock options granted               $ 7,448,230 $ 2,227,281  
Common stock, par value               $ 0.0001 $ 0.0001  
Warrant [Member]                    
Warrants exercise price       $ 3.50            
Common stock issued, Shares   350,856                
Warrants to purchase common stock   578,891                
Third party                    
Common stock repurchased, Shares             520,000      
Common stock repurchased, Value             $ 522,500      
Escrow agent                    
Share repurchase cost             $ 2,500      
Investor Two | Subscription Agreement [Member]                    
Common shares sold for cash, shares                 939,450  
Share price                 $ 2.25  
Investor One | Subscription Agreement [Member]                    
Common shares sold for cash, shares                 3,107,000  
Share price                 $ 1.75  
Investor                    
Common shares sold for cash, shares               138,595    
Description of purchage agreements       The Company entered into a purchase agreement with several third-party institutional investors for the purchase of 1,714,288 units in a registered direct offering, for gross proceeds of $6,000,008 before placement agent fees and other offering expenses payable by the Company. Each unit was sold at a public offering price of $3.50 and consists of one share of common stock and a warrant to purchase one share of common stock. The Company received net cash proceeds of $5,103,704, net of cash paid for placement agent fees and other offering expenses.            
Investor | Subscription Agreement [Member]                    
Common shares sold for cash                 $ 7,064,717  
Investment banking firm                 486,296  
Consulting companies [Member] | Consulting agreements                    
Common shares issued for services               $ 1,318,600 $ 1,371,450  
Common shares issued for services, Shares               537,380 505,679  
Stock-based compensation expense               $ 1,077,442 $ 865,700  
Decrease in accrued liabilities               116,575 10,000  
Prepaid expense               124,583 $ 495,750  
Accredited Investor [Member]                    
Common stock issued, Shares     2,000,000             3,000,000
Common stock issued                   $ 3,000,000
Accredited Investor [Member] | Subscription Agreement [Member] | Avalon (Shanghai) Healthcare Technology Co., Ltd.                    
Share price           $ 1.20        
Supplementary agreement related to share subscription, description           The Company, Avalon Shanghai, DOING and March 2017 Accredited Investor entered into a Supplementary Agreement Related to Share Subscription pursuant to which Avalon Shanghai agreed to pay RMB 8,256,000 (approximately $1.3 million based on the exchange rate on April 23, 2018) to DOING representing one-third of the DOING Investment plus 20% interest for the one-third DOING Investment resulting in a reduction in the March 2017 Shares by one-third to 2,000,000 shares. Further, the parties agreed that the BCC Repayment Obligation was extended to July 31, 2018. The $1 million BCC Repayment Obligation and related interest was paid in full in May 2018.        
Annual interest           20.00%        
Sales Agreement [Member]                    
Common shares sold for cash               $ 261,206    
Common stock, par value $ 0.0001             $ 0.0001    
Other offering expenses               $ 12,530    
Average price to investors $ 1.98             $ 1.98    
Maximum aggregate offering price $ 20,000,000                  
Option [Member]                    
Intrinsic values of stock options outstanding               $ 3,259,900    
Stock options exercisable               $ 3,171,746    
Fair values of options granted, description               The fair values of options granted during the year ended December 31, 2019 were estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions: volatility of 140.57% - 151.70%, risk-free rate of 1.55% - 2.49%, annual dividend yield of 0% and expected life of 3.00 – 5.00 years.    
Fair value of the options granted               $ 6,461,970